BioCardia completes low-dose enrollment in CardiALLO allogeneic MSC HFrEF trial

BioCardia, Inc.

Enrolled and dosed 3 patients in low-dose cohort (20M cells) of Phase I/II CardiALLO trial.
Trial is first prospective allogeneic MSC study targeting HFrEF patients with elevated heart stress/inflammation markers.
DSMB safety review expected March 2025; next dose escalation (100M cells) to follow.
Used Morph DNA steerable guide for enhancing cell delivery during treatment procedures.
Program aims to support pivotal US studies and conditional time-limited approval in Japan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.